Shin Joonggyeong, Yim Eunsang, Kang Chang Moo
Yonsei University College of Medicine, Seoul, Korea.
Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Yonsei University College of Medicine, Seoul, Korea.
Korean J Clin Oncol. 2023 Dec;19(2):88-92. doi: 10.14216/kjco.23016. Epub 2024 Dec 31.
A 78-year-old female patient was initially treated with laparoscopic radical cholecystectomy for gallbladder cancer (pT2aN1M0, stage IIIB). The patient then received adjuvant chemotherapy with gemcitabine. After completion of adjuvant chemotherapy, multiple lymph node metastases were observed in follow-up computed tomography (CT) scan, but the patient refused to go through further chemotherapy. One year after the recurrence, carbohydrate antigen 19-9 (CA19-9) level was 1,925 U/mL with follow-up high-resolution CT/abdomen-pelvic CT showing the increased size of multiple lymph node metastases, and the patient began to undergo Viscum album therapy (0.2 mg, subcutaneously, three times a week). After the V. album therapy was initiated, a decrease in the size of metastatic lymph nodes and CA19-9 level, which was decreased to 252 U/mL, was observed. Seventeen months after continuous V. album therapy, the patient agreed to have palliative chemotherapy. The patient underwent gemcitabine plus cisplatin chemotherapy and showed stable disease during follow-up. This case report suggests that V. album therapy showed anticancer effects and may act as a bridge to palliative chemotherapy for patients with inappropriate general conditions to undergo chemotherapy for recurrent gallbladder cancer.
一名78岁女性患者最初接受了腹腔镜胆囊癌根治术(pT2aN1M0,ⅢB期)。随后患者接受了吉西他滨辅助化疗。辅助化疗结束后,随访计算机断层扫描(CT)发现多处淋巴结转移,但患者拒绝进一步化疗。复发一年后,糖类抗原19-9(CA19-9)水平为1925 U/mL,随访高分辨率CT/腹盆腔CT显示多处淋巴结转移灶增大,患者开始接受欧洲红豆杉治疗(0.2 mg,皮下注射,每周三次)。开始欧洲红豆杉治疗后,观察到转移淋巴结大小减小,CA19-9水平降至252 U/mL。持续进行欧洲红豆杉治疗17个月后,患者同意接受姑息化疗。患者接受了吉西他滨联合顺铂化疗,随访期间病情稳定。本病例报告表明,欧洲红豆杉治疗显示出抗癌作用,对于因一般状况不佳而不适于接受复发性胆囊癌化疗的患者,它可能起到通向姑息化疗的桥梁作用。